Clinical Study of Sitaglitat Sodium Combined with Degu Asparton Insulin in the Treatment of Type 2 Diabetes Mellitus
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
目的 探讨西格列他钠联合德谷门冬双胰岛素治疗2型糖尿病的临床疗效.方法 选取2022年8月—2023年5月威海第970医院内分泌科收治的应用口服降糖药或预混人胰岛素治疗效果不佳的84例2型糖尿病患者为研究对象,以随机数表法分为研究组(n=42)、对照组(n=42),两组均给予常规治疗措施,对照组采用德谷门冬双胰岛素治疗,研究组在对照组基础上联合西格列他钠治疗.比较两组糖化血红蛋白(Glycosyl-ated Hemoglobin A1c,HbA1c)、空腹血糖(Fasting Plasma Glucose,FPG)、餐后 2 h血糖(2-hours Postprandial Plasma Glucose,2 hPG)、胰岛素的用量、空腹胰岛素(Fasting Insulin,FINS)、胰岛素抵抗指数(Homeostatic Model Assessment-Insulin Resistance,HOMA-IR)、胰岛β细胞功能指数(Homeostasis Model Assessment-β,HOMA-β)、体重指数(Body Mass Index,BMI)及低血糖发生情况.结果 治疗12周后,研究组HbA1c、FPG、2 hPG、胰岛素用量、HOMA-IR水平低于对照组,而FINS、HOMA-β水平高于对照组,差异有统计学意义(P均<0.05);两组体重指数、低血糖发生情况比较,差异无统计学意义(P均>0.05).结论 德谷门冬双胰岛素联合西格列他钠对2型糖尿病患者疗效显著,能有效控制其血糖水平;西格列他钠可有效改善患者胰岛功能,减轻胰岛素抵抗,减少胰岛素用量,未增加体重指数及低血糖发生率.
Objective To investigate the clinical effect of sitaglitat sodium therapy combined with Degu asparton insu-lin in the treatment of type 2 diabetes mellitus.Methods A total of 84 patients with type 2 diabetes who had poor treatment effect with oral hypoglycemic agents or premix human insulin treated in the Endocrinology Department of Weihai 970th Hospital from August 2022 to May 2023 were selected as the study objects and divided into study group(n=42)and control group(n=42)by random number table method.Both groups were given conventional treatment,the control group was treated with Degu asparton insulin,and the study group was treated with sitaglitat sodium on the ba-sis of the control group.The glyclated hemoglobin(HbA1c),fasting plasma glucose(FPG),2 hour postprandial plasma glucose(2 hPG),insulin dosage,fasting insulin(FINS),Homeostatic Model Assessment-insulin resistance(HOMA-IR),Homeostasis Model Assessment-β(HOMA-β),body mass index and incidence of hypoglycemia were compared between the two groups.Results After 12 weeks of treatment,HbA1c,FPG,2 hPG,insulin dosage and HOMA-IR lev-els in the study group were lower than those in the control group,while FINS and HOMA-β levels were higher than those in the control group,the differences were statistically significant(all P<0.05).There were no significant differ-ences in body mass index and the incidence of hypoglycemia between the two groups(both P>0.05).Conclusion Degu asparton insulin combined with sitaglitat sodium has significant effect on type 2 diabetes patients and can effectively control their blood glucose level.Sitaglitat sodium can effectively improve the islet function of patients,reduce insulin resistance,reduce insulin dosage,and do not increase body mass index and incidence of hypoglycemia.
NETL
NSTL
万方数据
